Added to YB: 2026-07-14
Pitch date: 2026-07-10
SMMT [bearish]
Summit Therapeutics Inc.
-1.26%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Market Cap
$11.8B
Pitch Price
$15.11
Price Target
5.90 (-61%)
Dividend
N/A
EV/EBITDA
-9.24
P/E
-9.57
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Can we reach the Summit? ($SMMT)
SMMT (short): Short thesis, PT $5.90 vs $15.52 (-62%). One-drug biotech (ivonescimab, licensed from Akeso) at $12B on hype. HARMONi missed OS (HR 0.79, p=0.057); HARMONi-3 missed interim PFS. 69% grade 3+ AEs, 24.8% hemorrhage. Nov 14 2026 FDA PDUFA binary risk; BeyondSpring CRL precedent. 1.6yr runway, pulled $500M raise. Floor $6-8.
Read full article (7 min)